The development program for Eli Lilly & Co.'s Lartruvo (olaratumab) is yet another demonstration of the flexibility FDA will afford rare diseases; the drug was cleared for a relatively broad indication for soft tissue sarcoma based on a trial that included 25 subtypes of the disease.
Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas
Accelerated filing was supported by trial of patients with 25 subtypes of soft tissue sarcoma and confirmatory study will span 50 kinds.